Abbvie Drug Patent Portfolio

Abbvie owns 68 orange book drugs protected by 490 US patents with Creon having the least patent protection, holding only 1 patent. And Kaletra with maximum patent protection, holding 49 patents. Given below is the list of Abbvie's drug patents along with their expiration dates.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11717515	Treatment of migraine	22 Dec, 2041	Active
US11857542	Treatment of migraine	22 Dec, 2041	Active
US12070450	Treatment of migraine	22 Dec, 2041	Active
US11690845	Methods of administering elagolix	27 Aug, 2040	Active
US11542239	Elagolix sodium compositions and processes	23 Jul, 2039	Active
US10610518	Presbyopia treatments	24 Apr, 2039	Active
US11285134	Presbyopia treatments	24 Apr, 2039	Active
US12083227	Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis	20 Aug, 2038	Active
US11690854	Methods of treating heavy menstrual bleeding	19 Apr, 2038	Active
US11564922	Methods of treating crohn's disease and ulcerative colitis	09 Mar, 2038	Active
US11607411	Methods of treating Crohn's disease and ulcerative colitis	09 Mar, 2038	Active
US11246866	Solid pharmaceutical compositions for treating HCV	24 Dec, 2036	Active
US10202393	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US10344036	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof	17 Oct, 2036	Active
US10519164	Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US10550126	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US10597400	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	17 Oct, 2036	Active
US10730883	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US10981923	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US10981924	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US10995095	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	17 Oct, 2036	Active
US11186584	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11198697	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11365198	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11512092	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11524964	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11535624	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11535625	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11535626	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11661425	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11680069	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11718627	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11767326	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11773105	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11773106	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11780847	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11780848	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11787815	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11795175	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11976077	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof	17 Oct, 2036	Active
US11993605	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US11993606	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US12077545	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US9951080	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036	Active
US9963459	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof	17 Oct, 2036	Active
US10537572	Methods of administering elagolix	01 Sep, 2036	Active
US10682351	Methods of administering elagolix	01 Sep, 2036	Active
US11246866	Solid pharmaceutical compositions for treating HCV	24 Jun, 2036	Active
US9321807	Crystal forms	05 Dec, 2035	Active
USRE48923	Crystal forms	08 Nov, 2035	Active
US9321807	Crystal forms	05 Jun, 2035	Active
USRE48923	Crystal forms	08 May, 2035	Active
US10117836	Tablet formulation for CGRP active compounds	30 Jan, 2035	Active
US11925709	Tablet formulation for CGRP active compounds	30 Jan, 2035	Active
US10105365	Solid antiviral dosage forms	02 Jan, 2035	Active
US9333204	Solid antiviral dosage forms	02 Jan, 2035	Active
US9744170	Solid antiviral dosage forms	02 Jan, 2035	Active
US9492316	Prostamide-containing intraocular implants and methods of use thereof	31 Oct, 2034	Active
US9980974	Prostamide-containing intraocular implants and methods of use thereof	31 Oct, 2034	Active
US10286029	Method for treating HCV	14 Sep, 2034	Active
US11484534	Methods for treating HCV	14 Sep, 2034	Active
US9669974	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	11 May, 2034	Active
US10286029	Method for treating HCV	14 Mar, 2034	Active
US11484534	Methods for treating HCV	14 Mar, 2034	Active
US10881659	Methods of treating heavy menstrual bleeding	14 Mar, 2034	Active
US11045470	Methods of treating heavy menstrual bleeding	14 Mar, 2034	Active
US11344551	Methods of treating heavy menstrual bleeding	14 Mar, 2034	Active
US11707464	Methods of treating heavy menstrual bleeding	14 Mar, 2034	Active
US9676525	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	07 Feb, 2034	Active
US8912210	Piperidinone carboxamide azaindane CGRP receptor antagonists	23 Dec, 2033	Active
US10201542	Formulations of pyrimidinedione derivative compounds	18 Oct, 2033	Active
US9629841	Formulations of pyrimidinedione derivative compounds	18 Oct, 2033	Active
US10993942	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	06 Sep, 2033	Active
US11110087	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	06 Sep, 2033	Active
US11413282	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	06 Sep, 2033	Active
US11590128	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	06 Sep, 2033	Active
US9539251	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	06 Sep, 2033	Active
US9708371	Treatments for gastrointestinal disorders	16 Aug, 2033	Active
USRE47221	Tricyclic compounds	16 Aug, 2033	Active
US10188632	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US11007179	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US11090291	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US11160792	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US11229627	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US11311516	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US11484527	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US9675587	Opioid receptor modulator dosage formulations	14 Mar, 2033	Active
US9850246	Process for making CGRP receptor antagonists	13 Mar, 2033	Active
US8937150	Anti-viral compounds	18 Nov, 2032	Active
US8466159	Methods for treating HCV	04 Sep, 2032	Active
US8492386	Methods for treating HCV	04 Sep, 2032	Active
US8680106	Methods for treating HCV	04 Sep, 2032	Active
US8685984	Methods for treating HCV	04 Sep, 2032	Active
US8648037	Macrocyclic proline derived HCV serine protease inhibitors	19 Jul, 2032	Active
US8754096	Piperidinone carboxamide azaindane CGRP receptor antagonists	19 Jul, 2032	Active
US8969566	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	15 Jun, 2032	Active
US9284314	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	15 Jun, 2032	Active
US9695122	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	15 Jun, 2032	Active
US8865937	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide	23 May, 2032	Active
US11369599	Melt-extruded solid dispersions containing an apoptosis-inducing agent	23 May, 2032	Active
US8937150	Anti-viral compounds	18 May, 2032	Active
US10201541	Compositions and methods for treating HCV	17 May, 2032	Active
US10201584	Compositions and methods for treating HCV	17 May, 2032	Active
US8561859	Dispensing device	16 Apr, 2032	Active
US8691938	Anti-viral compounds	13 Apr, 2032	Active
US8722657	Salts and crystalline forms of an apoptosis-inducing agent	29 Jan, 2032	Active
US8648037	Macrocyclic proline derived HCV serine protease inhibitors	19 Jan, 2032	Active
US10730873	Salts and crystalline forms of an apoptosis-inducing agent	21 Nov, 2031	Active
US9499545	Piperidinone carboxamide azaindane CGRP receptor antagonists	10 Nov, 2031	Active
US9833448	Piperidinone carboxamide azaindane CGRP receptor antagonists	10 Nov, 2031	Active
US8748573	Formulations comprising linaclotide	30 Oct, 2031	Active
US8802628	Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration	30 Oct, 2031	Active
US8420596	Macrocyclic hepatitis C serine protease inhibitors	10 Oct, 2031	Active
US8471025	Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt	12 Aug, 2031	Active
US10675325	Stable formulations of linaclotide	11 Aug, 2031	Active
US10702576	Stable formulations of linaclotide	11 Aug, 2031	Active
US8629185	7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof	15 Jul, 2031	Active
US8546399	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases	27 Jun, 2031	Active
US8686026	Solid compositions	09 Jun, 2031	Active
US9586978	Anti-viral compounds	06 May, 2031	Active
US8420596	Macrocyclic hepatitis C serine protease inhibitors	10 Apr, 2031	Active
US9044480	Compositions and methods for treating HCV	10 Apr, 2031	Active
US8920392	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	26 Mar, 2031	Active
US8481598	Stable dosage forms of levomilnacipran	02 Mar, 2031	Active
US8292129	Dispensing device	25 Feb, 2031	Active
US8933030	Treatments for gastrointestinal disorders	17 Feb, 2031	Active
US8247400	Cephem compounds useful for the treatment of bacterial infections	10 Feb, 2031	Active
US8962629	Tricyclic compounds	15 Jan, 2031	Active
US10028937	Anti-viral compounds	10 Dec, 2030	Active
US10039754	Anti-viral compounds	10 Dec, 2030	Active
US9586978	Anti-viral compounds	06 Nov, 2030	Active
US8835455	Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt	08 Oct, 2030	Active
US9629861	Compositions and methods for treating bacterial infections using ceftaroline	21 Sep, 2030	Active
US10028937	Anti-viral compounds	10 Jun, 2030	Active
US10039754	Anti-viral compounds	10 Jun, 2030	Active
US9006387	Anti-viral compounds	10 Jun, 2030	Active
US9174982	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases	26 May, 2030	Active
US10500214	Formulations of deoxycholic acid and salts thereof	02 Mar, 2030	Active
US8101593	Formulations of deoxycholic acid and salts thereof	02 Mar, 2030	Active
US8367649	Formulations of deoxycholic acid and salts thereof	02 Mar, 2030	Active
US8653058	Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits	02 Mar, 2030	Active
US9198871	Delayed release pancreatin compositions	07 Feb, 2030	Active
US8058291	Methods and compositions for the treatment of CNS-related conditions	05 Dec, 2029	Active
US10449173	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	06 Nov, 2029	Active
US9259388	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	06 Nov, 2029	Active
US8039009	Modified release formulations of memantine oral dosage forms	24 Sep, 2029	Active
US7994220	Milnacipran for the long-term treatment of fibromyalgia syndrome	19 Sep, 2029	Active
US7737142	(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists	17 Sep, 2029	Active
US8642538	Macrocyclic hepatitis C serine protease inhibitors	10 Sep, 2029	Active
US7842714	Ketorolac tromethamine compositions for treating ocular pain	15 Aug, 2029	Active
USRE47350	Pharmaceutical formulations containing dopamine receptor ligands	16 Jul, 2029	Active
USRE49110	Pharmaceutical formulations containing dopamine receptor ligands	16 Jul, 2029	Active
USRE49302	Pharmaceutical formulations containing dopamine receptor ligands	16 Jul, 2029	Active
US7419983	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	06 Jul, 2029	Active
US7741356	Compounds as opioid receptor modulators	27 May, 2029	Active
US8188104	Anti-infective agents and uses thereof	17 May, 2029	Active
US7799336	Hypotensive lipid-containing biodegradable intraocular implants and related methods	24 Apr, 2029	Active
US8039009	Modified release formulations of memantine oral dosage forms	24 Mar, 2029	Active
US7943621	Salts of piperazine compounds as D3/D2 antagonists	16 Dec, 2028	Active
US9139536	Anti-infective agents and uses thereof	09 Nov, 2028	Active
US11459305	Processes for the preparation of uracil derivatives	07 Nov, 2028	Active
US8501238	Anti-infective agents and uses thereof	17 Sep, 2028	Active
US8691860	Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028	Active
US9115091	Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028	Active
US9364489	Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028	Active
US9789125	Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028	Active
US8025899	Solid pharmaceutical dosage form	14 Jun, 2028	Active
US8217083	Mesalamine suppository	06 Jun, 2028	Active
US8436051	Mesalamine suppository	06 Jun, 2028	Active
US6900175	Methods of administering dalbavancin for treatment of bacterial infections	23 May, 2028	Active
US8242294	Synthetic bile acid compositions and methods	16 May, 2028	Active
US8377952	Solid pharmaceutical dosage formulation	22 Apr, 2028	Active
US8512717	Compositions for delivery of therapeutics into the eyes and methods for making and using same	07 Mar, 2028	Active
US9192571	Ketorolac tromethamine compositions for treating or preventing ocular pain	07 Mar, 2028	Active
US8461140	Synthetic bile acid compositions and methods	21 Feb, 2028	Active
US8546367	Synthetic bile acid compositions and methods	21 Feb, 2028	Active
US8883770	Synthetic bile acid compositions and methods	21 Feb, 2028	Active
US9522155	Synthetic bile acid compositions and methods	21 Feb, 2028	Active
US9636349	Synthetic bile acid compositions and methods	21 Feb, 2028	Active
US9949986	Synthetic bile acid compositions and methods	21 Feb, 2028	Active
US8664215	Ocular allergy treatments with alcaftadine	23 Dec, 2027	Active
US8025899	Solid pharmaceutical dosage form	14 Dec, 2027	Active
US7622130	Methods and compositions for the non-surgical removal of fat	10 Dec, 2027	Active
US7754230	Methods and related compositions for reduction of fat	10 Dec, 2027	Active
US8008338	Ketorolac tromethamine compositions for treating or preventing ocular pain	24 Nov, 2027	Active
US8377952	Solid pharmaceutical dosage formulation	22 Oct, 2027	Active
US7838552	Compositions comprising nebivolol	04 Oct, 2027	Active
US7851504	Enhanced bimatoprost ophthalmic solution	13 Jun, 2027	Active
US8008338	Ketorolac tromethamine compositions for treating or preventing ocular pain	24 May, 2027	Active
US8206737	Hypotensive lipid-containing biodegradable intraocular implants and related methods	07 Apr, 2027	Active
US10617695	Ophthalmic compositions containing alcaftadine	19 Mar, 2027	Active
US8470347	Self-emulsifying active substance formulation and use of this formulation	17 Mar, 2027	Active
US10441543	Processes for making cyclic lipid implants for intraocular use	19 Dec, 2026	Active
US9149428	Processes for making cyclic lipid implants for intraocular use	19 Dec, 2026	Active
US7612087	Heterocyclic compounds as inhibitors of beta-lactamases	12 Nov, 2026	Active
US8470347	Self-emulsifying active substance formulation and use of this formulation	17 Sep, 2026	Active
US7304036	Methods and compositions for the treatment of gastrointestinal disorders	30 Aug, 2026	Active
US7803838	Compositions comprising nebivolol	29 Aug, 2026	Active
US8168209	Method and composition for administering an NMDA receptor antagonist to a subject	22 May, 2026	Active
US8173708	Method and composition for administering an NMDA receptor antagonist to a subject	22 May, 2026	Active
US8283379	Methods and compositions for the treatment of CNS-related conditions	22 May, 2026	Active
US8329752	Composition for administering an NMDA receptor antagonist to a subject	22 May, 2026	Active
US8362085	Method for administering an NMDA receptor antagonist to a subject	22 May, 2026	Active
US8598233	Method for administering an NMDA receptor antagonist to a subject	22 May, 2026	Active
USRE43879	Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug	11 Jan, 2026	Active
US7112592	Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents	07 Jan, 2026	Active
US8168209	Method and composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025	Active
US8173708	Method and composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025	Active
US8283379	Methods and compositions for the treatment of CNS-related conditions	22 Nov, 2025	Active
US8329752	Composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025	Active
US8362085	Method for administering an NMDA receptor antagonist to a subject	22 Nov, 2025	Active
US8598233	Method for administering an NMDA receptor antagonist to a subject	22 Nov, 2025	Active
US8293794	Methods and compositions for the treatment of CNS-related conditions	22 Nov, 2025	Active
US8338485	Compositions for the treatment of CNS-related conditions	22 Nov, 2025	Active
US8338486	Methods for the treatment of CNS-related conditions	22 Nov, 2025	Active
US8580858	Compositions for the treatment of CNS-related conditions	22 Nov, 2025	Active
US8298556	Methods and related compositions for the non-surgical removal of fat	03 Aug, 2025	Active
US8309613	Solid pharmaceutical dosage form	24 Jun, 2025	Active
US8278353	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8299118	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8309605	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8338479	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8524777	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8586630	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8772338	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8933120	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US8933127	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US9155716	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US9241918	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025	Active
US10213415	Compounds as opioid receptor modulators	14 Mar, 2025	Active
US7786158	Compounds as opioid receptor modulators	14 Mar, 2025	Active
US8344011	Compounds as opioid receptor modulators	14 Mar, 2025	Active
US8609709	Compounds as opioid receptor modulators	14 Mar, 2025	Active
US8772325	Compounds as opioid receptor modulators	14 Mar, 2025	Active
US9205076	Compounds as opioid receptor modulators	14 Mar, 2025	Active
US9700542	Compounds as opioid receptor modulators	14 Mar, 2025	Active
US8268349	Solid pharmaceutical dosage form	25 Feb, 2025	Active
US8399015	Solid pharmaceutical dosage form	25 Feb, 2025	Active
US8691878	Solid pharmaceutical dosage form	25 Feb, 2025	Active
US8673341	Intraocular pressure reduction with intracameral bimatoprost implants	19 Feb, 2025	Active
US8846066	Methods and related compositions for reduction of fat and skin tightening	08 Feb, 2025	Active
US7259186	Salts of fenofibric acid and pharmaceutical formulations thereof	07 Jan, 2025	Active
US8309613	Solid pharmaceutical dosage form	24 Dec, 2024	Active
US8207215	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 Nov, 2024	Active
US8377982	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 Nov, 2024	Active
US8541463	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 Nov, 2024	Active
US7056927	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	10 Sep, 2024	Expired
US8629111	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024	Expired
US8633162	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024	Expired
US8642556	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024	Expired
US8648048	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024	Expired
US8685930	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024	Expired
US9248191	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024	Expired
US8268349	Solid pharmaceutical dosage form	25 Aug, 2024	Expired
US8399015	Solid pharmaceutical dosage form	25 Aug, 2024	Expired
US8691878	Solid pharmaceutical dosage form	25 Aug, 2024	Expired
US8992952	Compositions for delivery of therapeutics into the eyes and methods for making and using same	05 Aug, 2024	Expired
US7176211	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	06 Jul, 2024	Expired
US8207215	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024	Expired
US8377982	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024	Expired
US8541463	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024	Expired
US8648107	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024	Expired
US8906950	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024	Expired
US8946281	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024	Expired
US9216127	Burial vault and method for customizing a burial vault	28 May, 2024	Expired
US9216167	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024	Expired
US7351404	Method of enhancing hair growth	25 May, 2024	Expired
US8101161	Method of enhancing hair growth	25 May, 2024	Expired
US10398707	Hypotensive lipid-containing biodegradable intraocular implants and related implants	30 Apr, 2024	Expired
US8858961	Compositions containing alpha-2-adrenergic agonist components	02 Mar, 2024	Expired
US7371727	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024	Expired
US7704947	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024	Expired
US7745409	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024	Expired
US8080526	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024	Expired
US8110553	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024	Expired
US7115564	Stable pharmaceutical compositions of dalbavancin and methods of administration	14 Nov, 2023	Expired
US7119061	Dalbavancin compositions for treatment of bacterial infections	14 Nov, 2023	Expired
US8143212	Dalbavancin compositions for treatment of bacterial infections	14 Nov, 2023	Expired
US6899717	Methods and apparatus for delivery of ocular implants	01 Nov, 2023	Expired
US8858961	Compositions containing alpha-2-adrenergic agonist components	02 Sep, 2023	Expired
US8038988	Method of enhancing hair growth	25 Aug, 2023	Expired
US8263054	Method of enhancing hair growth	25 Aug, 2023	Expired
US7276249	Nanoparticulate fibrate formulations	21 Feb, 2023	Expired
US7320802	Methods of treatment using nanoparticulate fenofibrate compositions	21 Feb, 2023	Expired
US6916941	Crystalline composition containing escitalopram	12 Feb, 2023	Expired
US7420069	Crystalline composition containing escitalopram	12 Feb, 2023	Expired
US7323463	Combination of brimonidine and timolol for topical ophthalmic use	19 Jan, 2023	Expired
US8632760	Method of enhancing hair growth	15 Jan, 2023	Expired
US8758733	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	15 Jan, 2023	Expired
US8926953	Method of enhancing hair growth	15 Jan, 2023	Expired
US8986715	Method of enhancing hair growth	15 Jan, 2023	Expired
US9216183	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	15 Jan, 2023	Expired
US9226931	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	15 Jan, 2023	Expired
US6602911	Methods of treating fibromyalgia	14 Jan, 2023	Expired
US10076526	Ocular implant made by a double extrusion process	09 Jan, 2023	Expired
US10702539	Ocular implant made by a double extrusion process	09 Jan, 2023	Expired
US8034366	Ocular implant made by a double extrusion process	09 Jan, 2023	Expired
US8034370	Ocular implant made by a double extrusion process	09 Jan, 2023	Expired
US8506987	Ocular implant made by a double extrusion process	09 Jan, 2023	Expired
US9192511	Ocular implant made by a double extrusion process	09 Jan, 2023	Expired
US7834020	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Dec, 2022	Expired
US8193195	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Dec, 2022	Expired
US8236804	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride	05 Dec, 2022	Expired
US8673921	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Dec, 2022	Expired
US6916941	Crystalline composition containing escitalopram	12 Aug, 2022	Expired
US7420069	Crystalline composition containing escitalopram	12 Aug, 2022	Expired
US7834020	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Jun, 2022	Expired
US8193195	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Jun, 2022	Expired
US8236804	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride	05 Jun, 2022	Expired
US8673921	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Jun, 2022	Expired
US6911214	Flavoring systems for pharmaceutical compositions and methods of making such compositions	28 May, 2022	Expired
US7030149	Combination of brimonidine timolol for topical ophthalmic use	19 Apr, 2022	Expired
US7320976	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US7642258	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US8133890	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US8354409	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US8748425	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US9474751	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US9770453	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US9907801	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US9907802	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022	Expired
US6641834	Compositions containing alpha-2-adrenergic agonist components	28 Jan, 2022	Expired
US6673337	Compositions containing alpha-2-adrenergic agonist components	26 Jan, 2022	Expired
US7388029	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	21 Jan, 2022	Expired
US6627210	Compositions containing α-2-adrenergic agonist components	18 Jan, 2022	Expired
US6562873	Compositions containing therapeutically active components having enhanced solubility	10 Jan, 2022	Expired
US9295641	Compositions containing alpha-2-adrenergic agonist components	10 Jan, 2022	Expired
US9687443	Compositions containing alpha-2-adrenergic agonist components	10 Jan, 2022	Expired
US6906055	Phosphonocephem compound	15 Dec, 2021	Expired
US7419973	Phosphonocephem compound	15 Dec, 2021	Expired
US6911214	Flavoring systems for pharmaceutical compositions and methods of making such compositions	28 Nov, 2021	Expired
US8501219	Flavoring systems for pharmaceutical compositions and methods of making such compositions	28 Nov, 2021	Expired
US7767223	Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use	28 Nov, 2021	Expired
US6893662	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures	15 Nov, 2021	Expired
US8580302	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures	15 Nov, 2021	Expired
US9089492	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures	15 Nov, 2021	Expired
US6992110	Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain	05 Nov, 2021	Expired
US7888342	Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain	05 Nov, 2021	Expired
US6641834	Compositions containing alpha-2-adrenergic agonist components	28 Jul, 2021	Expired
US6673337	Compositions containing alpha-2-adrenergic agonist components	26 Jul, 2021	Expired
US8178554	Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents	24 Jul, 2021	Expired
US6627210	Compositions containing α-2-adrenergic agonist components	18 Jul, 2021	Expired
US10307368	Compositions containing alpha-2-adrenergic agonist components	10 Jul, 2021	Expired
US6562873	Compositions containing therapeutically active components having enhanced solubility	10 Jul, 2021	Expired
US9295641	Compositions containing alpha-2-adrenergic agonist components	10 Jul, 2021	Expired
US9687443	Compositions containing alpha-2-adrenergic agonist components	10 Jul, 2021	Expired
US7364752	Solid dispersion pharamaceutical formulations	10 May, 2021	Expired
US7179815	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	07 Mar, 2021	Expired
US8541466	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	31 Jan, 2021	Expired
US8906962	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	31 Jan, 2021	Expired
US9579270	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	31 Jan, 2021	Expired
US6872728	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	25 Jan, 2021	Expired
US7462625	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	25 Jan, 2021	Expired
US7141593	Pharmaceutical formulations	22 Nov, 2020	Expired
US7432294	Pharmaceutical formulations	22 Nov, 2020	Expired
US7364752	Solid dispersion pharamaceutical formulations	10 Nov, 2020	Expired
US7033605	Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor	20 Oct, 2020	Expired
US6726918	Methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020	Expired
US8043628	Methods for reducing edema	20 Oct, 2020	Expired
US8063031	Implants and methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020	Expired
US8088407	Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor	20 Oct, 2020	Expired
US9012437	Implants and methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020	Expired
US9283178	Methods for treating edema in the eye and intraocular implants for use therefor	20 Oct, 2020	Expired
US9592242	Methods for treating edema in the eye and intraocular implants for use therefor	20 Oct, 2020	Expired
US9775849	Implants and methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020	Expired
US6375986	Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate	21 Sep, 2020	Expired
US7141593	Pharmaceutical formulations	22 May, 2020	Expired
US7432294	Pharmaceutical formulations	22 May, 2020	Expired
US10272061	Compositions and methods for unoccluded transdermal oxybutynin therapy	26 Apr, 2020	Expired
US7029694	Compositions and methods for transdermal oxybutynin therapy	26 Apr, 2020	Expired
US7179483	Compositions and methods for transdermal oxybutynin therapy	26 Apr, 2020	Expired
US8241662	Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy	26 Apr, 2020	Expired
US6743441	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020	Expired
US7081249	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020	Expired
US7081250	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020	Expired
US7081251	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020	Expired
US7081252	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020	Expired
US6649180	Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups	13 Apr, 2020	Expired
US6333045	Aqueous liquid pharmaceutical composition comprised of gatifloxacin	20 Feb, 2020	Expired
US6051567	Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol	02 Feb, 2020	Expired
US6265392	Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol	02 Feb, 2020	Expired
US6274169	Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol	02 Feb, 2020	Expired
US7148359	Polymorph of a pharmaceutical	19 Jan, 2020	Expired
US6333045	Aqueous liquid pharmaceutical composition comprised of gatifloxacin	20 Aug, 2019	Expired
US6051567	Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol	02 Aug, 2019	Expired
US6265392	Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol	02 Aug, 2019	Expired
US6274169	Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol	02 Aug, 2019	Expired
US7148359	Polymorph of a pharmaceutical	19 Jul, 2019	Expired
US6419953	Controlled release formulation of divalproex sodium	18 Jun, 2019	Expired
US6511678	Controlled release formulation of divalproex sodium	18 Jun, 2019	Expired
US6528090	Controlled release formulation of divalproex sodium	18 Jun, 2019	Expired
US6528091	Controlled release formulation of divalproex sodium	18 Jun, 2019	Expired
US6713086	Controlled release formulation of divalproex sodium	18 Jun, 2019	Expired
US6720004	Controlled release formulation of divalproex sodium	18 Jun, 2019	Expired
US6419953	Controlled release formulation of divalproex sodium	18 Dec, 2018	Expired
US6511678	Controlled release formulation of divalproex sodium	18 Dec, 2018	Expired
US6528090	Controlled release formulation of divalproex sodium	18 Dec, 2018	Expired
US6528091	Controlled release formulation of divalproex sodium	18 Dec, 2018	Expired
US6713086	Controlled release formulation of divalproex sodium	18 Dec, 2018	Expired
US6720004	Controlled release formulation of divalproex sodium	18 Dec, 2018	Expired
US6417175	Phosphonocephem derivatives, process for the preparation of the same, and use thereof	17 Dec, 2018	Expired
US6136799	Cosolvent formulations	08 Oct, 2018	Expired
US6361758	Cosolvent formulations	08 Oct, 2018	Expired
US6074668	Container for an inhalation anesthetic	09 Jul, 2018	Expired
US6232333	Pharmaceutical composition	07 May, 2018	Expired
US6458818	Pharmaceutical composition	07 May, 2018	Expired
US6521651	Pharmaceutical composition	07 May, 2018	Expired
US6136799	Cosolvent formulations	08 Apr, 2018	Expired
US6361758	Cosolvent formulations	08 Apr, 2018	Expired
US6469035	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid	15 Mar, 2018	Expired
US6074670	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018	Expired
US6277405	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018	Expired
US6589552	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018	Expired
US6652881	Fenofibrate pharmaceutical composition having high bioavailability	09 Jan, 2018	Expired
US7037529	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018	Expired
US7041319	Fenofibrate pharmaceutical composition having high bioavailabilty	09 Jan, 2018	Expired
US6074668	Container for an inhalation anesthetic	09 Jan, 2018	Expired
US6232333	Pharmaceutical composition	07 Nov, 2017	Expired
US6458818	Pharmaceutical composition	07 Nov, 2017	Expired
US6521651	Pharmaceutical composition	07 Nov, 2017	Expired
US5990176	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jul, 2017	Expired
US6288127	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jul, 2017	Expired
US6444859	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jul, 2017	Expired
US6551616	Extended release formulations of erythromycin derivatives	15 Jul, 2017	Expired
US6348216	Ibuprofen and narcotic analgesic compositions	10 Jun, 2017	Expired
US6599531	Method of making ibuprofen and narcotic analgesic compositions	10 Jun, 2017	Expired
US6080428	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	27 May, 2017	Expired
US6010718	Extended release formulations of erythromycin derivatives	11 Apr, 2017	Expired
US5990176	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jan, 2017	Expired
US6288127	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jan, 2017	Expired
US6444859	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jan, 2017	Expired
US6037157	Method for improving pharmacokinetics	26 Dec, 2016	Expired
US6703403	Method for improving pharmacokinetics	26 Dec, 2016	Expired
US5863560	Compositions and methods for topical application of therapeutic agents	11 Sep, 2016	Expired
US6060085	Compositions and methods for topical application of therapeutic agents	11 Sep, 2016	Expired
US6620435	Compositions for topical application of therapeutic agents	11 Sep, 2016	Expired
US6106864	Pharmaceutical formulations containing darifenacin	21 Aug, 2016	Expired
US6284767	Retroviral protease inhibiting compounds	15 Aug, 2016	Expired
US6037157	Method for improving pharmacokinetics	26 Jun, 2016	Expired
US6703403	Method for improving pharmacokinetics	26 Jun, 2016	Expired
US5914332	Retroviral protease inhibiting compounds	13 Jun, 2016	Expired
US5880283	8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same	05 Jun, 2016	Expired
US6284767	Retroviral protease inhibiting compounds	15 Feb, 2016	Expired
US5597815	Prevention of hyperphosphatemia in kidney disorder patients	13 Jan, 2016	Expired
US5914332	Retroviral protease inhibiting compounds	13 Dec, 2015	Expired
US5880283	8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same	05 Dec, 2015	Expired
US5061703	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Oct, 2015	Expired
US5597815	Prevention of hyperphosphatemia in kidney disorder patients	13 Jul, 2015	Expired
US5744496	Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors	28 Apr, 2015	Expired
US5601839	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	26 Apr, 2015	Expired
US5834010	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	26 Apr, 2015	Expired
US5061703	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Apr, 2015	Expired
US5096890	Pyrrolidine derivatives	13 Mar, 2015	Expired
US5721244	Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs	24 Feb, 2015	Expired
US5648497	Retroviral protease inhibiting compounds	15 Jan, 2015	Expired
US5532241	Piperidines and piperazines	29 Sep, 2014	Expired
US5688819	Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	19 Aug, 2014	Expired
US5656650	Angiotensin II receptor blocking compositions	12 Aug, 2014	Expired
US5484801	Pharmaceutical composition for inhibiting HIV protease	28 Jul, 2014	Expired
US5648497	Retroviral protease inhibiting compounds	15 Jul, 2014	Expired
US5587497	19-nor-vitamin D compounds	24 Jun, 2014	Expired
US7189761	Nitric oxide donor composition and method for treatment of anal disorders	27 May, 2014	Expired
US5886036	Retroviral protease inhibiting compounds	19 May, 2014	Expired
US5474979	Nonirritating emulsions for sensitive tissue	17 May, 2014	Expired
US5948436	Pharmaceutical composition	13 Mar, 2014	Expired
US5541206	Retroviral protease inhibiting compounds	30 Jan, 2014	Expired
US5635523	Retroviral protease inhibiting compounds	30 Jan, 2014	Expired
US5674882	Retroviral protease inhibiting compounds	30 Jan, 2014	Expired
US5484801	Pharmaceutical composition for inhibiting HIV protease	28 Jan, 2014	Expired
US5587497	19-nor-vitamin D compounds	24 Dec, 2013	Expired
US5468743	Imidazo[2,1-b]benzazepine derivatives, compositions and method of use	21 Nov, 2013	Expired
US5886036	Retroviral protease inhibiting compounds	19 Nov, 2013	Expired
US6129930	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night	20 Sep, 2013	Expired
US6406715	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles	20 Sep, 2013	Expired
US6676967	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia	20 Sep, 2013	Expired
US6746691	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics	20 Sep, 2013	Expired
US6818229	Intermediate release nicotinic acid compositions for treating hyperlipidemia	20 Sep, 2013	Expired
US7011848	Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013	Expired
US7998506	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013	Expired
US5948436	Pharmaceutical composition	13 Sep, 2013	Expired
US5541170	Orally administrable pharmaceutical compositions	30 Jul, 2013	Expired
US5541171	Orally administrable pharmaceutical composition	30 Jul, 2013	Expired
US5541206	Retroviral protease inhibiting compounds	30 Jul, 2013	Expired
US5635523	Retroviral protease inhibiting compounds	30 Jul, 2013	Expired
US5674882	Retroviral protease inhibiting compounds	30 Jul, 2013	Expired
US5424078	Aqueous ophthalmic formulations and methods for preserving same	13 Dec, 2012	Expired
US8017655	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	27 Nov, 2012	Expired
US5246925	19-nor-vitamin D compounds for use in treating hyperparathyroidism	17 Oct, 2012	Expired
US5453510	Neuromuscular blocking agents	26 Sep, 2012	Expired
US6403649	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents	21 Sep, 2012	Expired

Latest Legal Activities on Abbvie's Drug Patents

Given below is the list of recent legal activities going on the following drug patents of Abbvie.

Activity	Date	Patent Number

Email Notification Critical	19 Jul, 2024	US11369599
Mail O.P. Petition Decision	19 Jul, 2024	US11369599
Mail-Petition Decision - Granted	16 Jul, 2024	US11369599
Mail-Petition Decision - Denied	16 Jul, 2024	US11369599
Petition Decision - Denied	15 Jul, 2024	US11369599
O.P. Petition Decision	15 Jul, 2024	US11369599
Petition Decision - Granted Critical	15 Jul, 2024	US11369599
Payment of Maintenance Fee, 12th Year, Large Entity	11 Jul, 2024	US8367649
Post Issue Communication - Certificate of Correction	08 Jul, 2024	US11542239
Post Issue Communication - Certificate of Correction	08 Jul, 2024	US11542239
Expire Patent Critical	08 Jul, 2024	US8193195 (Litigated)
Mail Certificate of Correction Memo	05 Jul, 2024	US11542239
Mail Certificate of Correction Memo	05 Jul, 2024	US11542239
Certificate of Correction Memo	02 Jul, 2024	US11542239
Certificate of Correction Memo	02 Jul, 2024	US11542239

Abbvie's Drug Patent Litigations

Abbvie's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 02, 2006, against patent number US8008338. The petitioner , challenged the validity of this patent, with Christopher A. Muller et al as the respondent. Click below to track the latest information on how companies are challenging Abbvie's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11110087	October, 2022	Final Written Decision - Appealed (16 Apr, 2024)	Genentech, Inc. et al.	Dr. Reddy's Laboratories, Inc. et al.
US10993942	February, 2022	Final Written Decision - Appealed (10 Aug, 2023)	Genentech, Inc. et al.	Dr. Reddy's Laboratories, Inc. et al.
US8648048	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US9248191	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US8642556	June, 2016	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8685930	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US8629111	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US8633162	June, 2016	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8629111	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Akorn, Inc.
US8648048	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US8685930	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Akorn, Inc.
US9248191	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8633162	January, 2017	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8642556	January, 2017	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Akorn, Inc.
US8673921	January, 2018	Terminated-Denied (23 Jul, 2018)	Merck Patentgesellschaft Mit Beschrankter Haftung	Argentum Pharmaceuticals LLC
US6649180	November, 2016	Terminated-Settled (19 Dec, 2017)	Qualicaps Co., Ltd.	Mylan Pharmaceuticals Inc.
US8642556	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8629111	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8648048	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8633162	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8685930	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US9248191	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8629111	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US9248191	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Akorn, Inc.
US8648048	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Akorn, Inc.
US8642556	January, 2017	FWD Entered (31 Mar, 2017)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8685930	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8633162	January, 2017	FWD Entered (31 Mar, 2017)	Allergan, Inc.	Akorn, Inc.
US8629111	June, 2016	Terminated-Settled (08 Dec, 2016)	Allergan, Inc.	Argentum Pharmaceuticals LLC
US8648048	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8685930	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8642556	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8633162	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8629111	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US7030149	March, 2015	Terminated-Denied (21 Sep, 2015)	Allergan Sales, LLC	Ferrum Ferro Capital, LLC
US8362085	December, 2014	Terminated-Denied (15 May, 2015)	Adamas Pharmaceuticals, Inc.	Ranbaxy, Inc.
US8008338	November, 2010	Decision (29 Mar, 2011)	Christopher A. Muller et al
US8470347	August, 2009	Decision (27 May, 2010)	Gunther Berndl et al
US7851504	January, 2009	Decision (10 May, 2010)	Chin-Ming Chang et al
US8008338	August, 2006	Decision (21 Dec, 2006)	Christopher A. Muller et al

Abbvie Drug Patents' Oppositions Filed in EPO

Abbvie drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 11, 2005, by Egis Gyogyszergyar Rt.. This opposition was filed on patent number EP02750846A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status

EP19729883A	Dec, 2022	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP17165207A	May, 2021	Generics (U.K.) Limited	Granted and Under Opposition
EP17182561A	Nov, 2019	Lederer & Keller Patentanwälte Partnerschaft mbB	Patent maintained as amended
EP03789744A	Jul, 2019	Fresenius Kabi Deutschland GmbH	Granted and Under Opposition
EP14774006A	May, 2019	Sandoz AG	Opposition rejected
EP15176068A	Apr, 2019	Aechter, Bernd	Revoked
EP14815668A	Oct, 2018	Epping Hermann Fischer Patentanwaltgesellschaft MBH	Patent maintained as amended
EP11791401A	May, 2018	Generics (U.K.) Limited	Revoked
EP10835061A	Feb, 2018	Generics (U.K.) Limited	Opposition rejected
EP14719977A	Jan, 2018	Generics (U.K.) Limited	Granted and Under Opposition
EP12753313A	Sep, 2017	Hexal AG	Revoked
EP11727080A	Apr, 2016	KELTIE LLP	Patent maintained as amended
EP11727080A	Apr, 2016	Ter Meer Steinmeister & Partner Patentanwälte mbB	Patent maintained as amended
EP05852057A	Dec, 2013	Elend, Almut Susanne	Revoked
EP10185774A	Dec, 2013	Generics [UK] Limited	Revoked
EP07017089A	Dec, 2013	Generics [UK] Limited	Revoked
EP03726234A	Oct, 2013	Hexal AG	Revoked
EP03726234A	Oct, 2013	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Revoked
EP03726234A	Oct, 2013	Generics [UK] Limited	Revoked
EP03726234A	Oct, 2013	Alfred E. Tiefenbacher GmbH & Co. KG	Revoked
EP03726234A	Oct, 2013	Teva Pharmaceutical Industries LTD.	Revoked
EP03726234A	Oct, 2013	STADA Arzneimittel AG	Revoked
EP10170038A	Mar, 2013	Generics [UK] Limited	Opposition rejected
EP06749777A	Jun, 2011	Merz Pharma GmbH & Co. KGaA	Revoked
EP04780382A	Jul, 2010	ALCON LABORATORIES, INC.	Patent maintained as amended
EP06738208A	Feb, 2010	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended
EP06738208A	Feb, 2010	Ratiopharm GmbH	Patent maintained as amended
EP04029282A	Oct, 2007	Ratiopharm GmbH	Revoked
EP04029282A	Oct, 2007	Krka, Tovarna Zdravil, d.d.	Revoked
EP04029282A	Oct, 2007	Generics [UK] Limited	Revoked
EP04029282A	Oct, 2007	Actavis Group hf	Revoked
EP04029282A	Oct, 2007	EGIS Gyógyszergyár Nyrt	Revoked
EP04029282A	Sep, 2007	Pliva Hrvatska D.O.O.	Revoked
EP03723781A	Jul, 2007	Abraxis BioScience, Inc.	Patent maintained as amended
EP03723781A	Jul, 2007	Baxter Healthcare Corporation	Patent maintained as amended
EP04029282A	Jan, 2007	SANDOZ AG	Revoked
EP02750846A	Oct, 2005	Egis Gyogyszergyar RT.	Revoked

Abbvie's Family Patents

Abbvie drugs have patent protection in a total of 74 countries. It's US patent count contributes only to 27.3% of its total global patent coverage. 15 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Abbvie Drug List

Given below is the complete list of Abbvie's drugs and the patents protecting them.

1. Acular Ls

Acular Ls is protected by 13 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8008338 (Pediatric)	Ketorolac tromethamine compositions for treating or preventing ocular pain	24 Nov, 2027 (3 years from now)	Active
US8008338	Ketorolac tromethamine compositions for treating or preventing ocular pain	24 May, 2027 (2 years from now)	Active
US8207215 (Pediatric)	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 Nov, 2024 (12 days from now)	Active
US8377982 (Pediatric)	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 Nov, 2024 (12 days from now)	Active
US8541463 (Pediatric)	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 Nov, 2024 (12 days from now)	Active
US8207215	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024 (5 months ago)	Expired
US8377982	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024 (5 months ago)	Expired
US8541463	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024 (5 months ago)	Expired
US8648107	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024 (5 months ago)	Expired
US8906950	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024 (5 months ago)	Expired
US8946281	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024 (5 months ago)	Expired
US9216127	Burial vault and method for customizing a burial vault	28 May, 2024 (5 months ago)	Expired
US9216167	Ketorolac tromethamine compositions for treating or preventing ocular pain	28 May, 2024 (5 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acular Ls's drug page

2. Acuvail

Acuvail is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7842714	Ketorolac tromethamine compositions for treating ocular pain	15 Aug, 2029 (4 years from now)	Active
US8512717	Compositions for delivery of therapeutics into the eyes and methods for making and using same	07 Mar, 2028 (3 years from now)	Active
US9192571	Ketorolac tromethamine compositions for treating or preventing ocular pain	07 Mar, 2028 (3 years from now)	Active
US8992952	Compositions for delivery of therapeutics into the eyes and methods for making and using same	05 Aug, 2024 (3 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acuvail's drug page

3. Aczone

Aczone is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5863560	Compositions and methods for topical application of therapeutic agents	11 Sep, 2016 (8 years ago)	Expired
US6060085	Compositions and methods for topical application of therapeutic agents	11 Sep, 2016 (8 years ago)	Expired
US6620435	Compositions for topical application of therapeutic agents	11 Sep, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aczone's drug page

4. Advicor

Advicor is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6469035	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid	15 Mar, 2018 (6 years ago)	Expired
US6080428	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	27 May, 2017 (7 years ago)	Expired
US6129930	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night	20 Sep, 2013 (11 years ago)	Expired
US6406715	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles	20 Sep, 2013 (11 years ago)	Expired
US6676967	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia	20 Sep, 2013 (11 years ago)	Expired
US6746691	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics	20 Sep, 2013 (11 years ago)	Expired
US6818229	Intermediate release nicotinic acid compositions for treating hyperlipidemia	20 Sep, 2013 (11 years ago)	Expired
US7011848	Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013 (11 years ago)	Expired
US7998506	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Advicor's drug page

5. Alphagan P

Alphagan P is protected by 16 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8858961 (Pediatric)	Compositions containing alpha-2-adrenergic agonist components	02 Mar, 2024 (8 months ago)	Expired
US8858961	Compositions containing alpha-2-adrenergic agonist components	02 Sep, 2023 (1 year, 2 months ago)	Expired
US6641834 (Pediatric)	Compositions containing alpha-2-adrenergic agonist components	28 Jan, 2022 (2 years ago)	Expired
US6673337 (Pediatric)	Compositions containing alpha-2-adrenergic agonist components	26 Jan, 2022 (2 years ago)	Expired
US6627210 (Pediatric)	Compositions containing α-2-adrenergic agonist components	18 Jan, 2022 (2 years ago)	Expired
US6562873 (Pediatric)	Compositions containing therapeutically active components having enhanced solubility	10 Jan, 2022 (2 years ago)	Expired
US9295641 (Pediatric)	Compositions containing alpha-2-adrenergic agonist components	10 Jan, 2022 (2 years ago)	Expired
US9687443 (Pediatric)	Compositions containing alpha-2-adrenergic agonist components	10 Jan, 2022 (2 years ago)	Expired
US6641834	Compositions containing alpha-2-adrenergic agonist components	28 Jul, 2021 (3 years ago)	Expired
US6673337	Compositions containing alpha-2-adrenergic agonist components	26 Jul, 2021 (3 years ago)	Expired
US6627210	Compositions containing α-2-adrenergic agonist components	18 Jul, 2021 (3 years ago)	Expired
US10307368	Compositions containing alpha-2-adrenergic agonist components	10 Jul, 2021 (3 years ago)	Expired
US6562873	Compositions containing therapeutically active components having enhanced solubility	10 Jul, 2021 (3 years ago)	Expired
US9295641	Compositions containing alpha-2-adrenergic agonist components	10 Jul, 2021 (3 years ago)	Expired
US9687443	Compositions containing alpha-2-adrenergic agonist components	10 Jul, 2021 (3 years ago)	Expired
US5424078 (Pediatric)	Aqueous ophthalmic formulations and methods for preserving same	13 Dec, 2012 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alphagan P's drug page

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

6. Asacol Hd

Asacol Hd is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6893662	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures	15 Nov, 2021 (3 years ago)	Expired
US8580302	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures	15 Nov, 2021 (3 years ago)	Expired
US9089492	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures	15 Nov, 2021 (3 years ago)	Expired
US5541170	Orally administrable pharmaceutical compositions	30 Jul, 2013 (11 years ago)	Expired
US5541171	Orally administrable pharmaceutical composition	30 Jul, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Asacol Hd's drug page

7. Avycaz

Avycaz is protected by 8 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8969566	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	15 Jun, 2032 (7 years from now)	Active
US9284314	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	15 Jun, 2032 (7 years from now)	Active
US9695122	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof	15 Jun, 2032 (7 years from now)	Active
US8471025	Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt	12 Aug, 2031 (6 years from now)	Active
US8835455	Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt	08 Oct, 2030 (5 years from now)	Active
US7612087	Heterocyclic compounds as inhibitors of beta-lactamases	12 Nov, 2026 (1 year, 11 months from now)	Active
US7112592	Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents	07 Jan, 2026 (1 year, 1 month from now)	Active
US8178554	Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents	24 Jul, 2021 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avycaz's drug page

8. Biaxin Xl

Biaxin Xl is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6551616	Extended release formulations of erythromycin derivatives	15 Jul, 2017 (7 years ago)	Expired
US6010718	Extended release formulations of erythromycin derivatives	11 Apr, 2017 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Biaxin Xl's drug page

9. Byvalson

Byvalson is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7838552	Compositions comprising nebivolol	04 Oct, 2027 (2 years from now)	Active
US7803838	Compositions comprising nebivolol	29 Aug, 2026 (1 year, 9 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byvalson's drug page

10. Calcijex

Calcijex is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6051567 (Pediatric)	Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol	02 Feb, 2020 (4 years ago)	Expired
US6265392 (Pediatric)	Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol	02 Feb, 2020 (4 years ago)	Expired
US6274169 (Pediatric)	Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol	02 Feb, 2020 (4 years ago)	Expired
US6051567	Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol	02 Aug, 2019 (5 years ago)	Expired
US6265392	Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol	02 Aug, 2019 (5 years ago)	Expired
US6274169	Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol	02 Aug, 2019 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Calcijex's drug page

11. Canasa

Canasa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8217083	Mesalamine suppository	06 Jun, 2028 (3 years from now)	Active
US8436051	Mesalamine suppository	06 Jun, 2028 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Canasa's drug page

12. Combigan

Combigan is protected by 11 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7323463	Combination of brimonidine and timolol for topical ophthalmic use	19 Jan, 2023 (1 year, 9 months ago)	Expired
US7030149	Combination of brimonidine timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US7320976	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US7642258	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US8133890	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US8354409	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US8748425	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US9474751	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US9770453	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US9907801	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired
US9907802	Combination of brimonidine and timolol for topical ophthalmic use	19 Apr, 2022 (2 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combigan's drug page

13. Creon

Creon is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9198871	Delayed release pancreatin compositions	07 Feb, 2030 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Creon's drug page

14. Dalvance

Dalvance is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6900175	Methods of administering dalbavancin for treatment of bacterial infections	23 May, 2028 (3 years from now)	Active
US7115564	Stable pharmaceutical compositions of dalbavancin and methods of administration	14 Nov, 2023 (1 year, 2 days ago)	Expired
US7119061	Dalbavancin compositions for treatment of bacterial infections	14 Nov, 2023 (1 year, 2 days ago)	Expired
US8143212	Dalbavancin compositions for treatment of bacterial infections	14 Nov, 2023 (1 year, 2 days ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dalvance's drug page

15. Delzicol

Delzicol is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6649180	Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups	13 Apr, 2020 (4 years ago)	Expired
US5541170	Orally administrable pharmaceutical compositions	30 Jul, 2013 (11 years ago)	Expired
US5541171	Orally administrable pharmaceutical composition	30 Jul, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Delzicol's drug page

16. Depakote Er

Depakote Er is protected by 12 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6419953 (Pediatric)	Controlled release formulation of divalproex sodium	18 Jun, 2019 (5 years ago)	Expired
US6511678 (Pediatric)	Controlled release formulation of divalproex sodium	18 Jun, 2019 (5 years ago)	Expired
US6528090 (Pediatric)	Controlled release formulation of divalproex sodium	18 Jun, 2019 (5 years ago)	Expired
US6528091 (Pediatric)	Controlled release formulation of divalproex sodium	18 Jun, 2019 (5 years ago)	Expired
US6713086 (Pediatric)	Controlled release formulation of divalproex sodium	18 Jun, 2019 (5 years ago)	Expired
US6720004 (Pediatric)	Controlled release formulation of divalproex sodium	18 Jun, 2019 (5 years ago)	Expired
US6419953	Controlled release formulation of divalproex sodium	18 Dec, 2018 (5 years ago)	Expired
US6511678	Controlled release formulation of divalproex sodium	18 Dec, 2018 (5 years ago)	Expired
US6528090	Controlled release formulation of divalproex sodium	18 Dec, 2018 (5 years ago)	Expired
US6528091	Controlled release formulation of divalproex sodium	18 Dec, 2018 (5 years ago)	Expired
US6713086	Controlled release formulation of divalproex sodium	18 Dec, 2018 (5 years ago)	Expired
US6720004	Controlled release formulation of divalproex sodium	18 Dec, 2018 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Depakote Er's drug page

17. Durysta

Durysta is protected by 10 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9492316	Prostamide-containing intraocular implants and methods of use thereof	31 Oct, 2034 (9 years from now)	Active
US9980974	Prostamide-containing intraocular implants and methods of use thereof	31 Oct, 2034 (9 years from now)	Active
US8629185	7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof	15 Jul, 2031 (6 years from now)	Active
US7799336	Hypotensive lipid-containing biodegradable intraocular implants and related methods	24 Apr, 2029 (4 years from now)	Active
US8206737	Hypotensive lipid-containing biodegradable intraocular implants and related methods	07 Apr, 2027 (2 years from now)	Active
US10441543	Processes for making cyclic lipid implants for intraocular use	19 Dec, 2026 (2 years from now)	Active
US9149428	Processes for making cyclic lipid implants for intraocular use	19 Dec, 2026 (2 years from now)	Active
US8673341	Intraocular pressure reduction with intracameral bimatoprost implants	19 Feb, 2025 (3 months from now)	Active
US10398707	Hypotensive lipid-containing biodegradable intraocular implants and related implants	30 Apr, 2024 (6 months ago)	Expired
US7033605	Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor	20 Oct, 2020 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Durysta's drug page

18. Enablex

Enablex is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6106864	Pharmaceutical formulations containing darifenacin	21 Aug, 2016 (8 years ago)	Expired
US5096890	Pyrrolidine derivatives	13 Mar, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Enablex's drug page

19. Fetzima

Fetzima is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8865937	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide	23 May, 2032 (7 years from now)	Active
US8481598	Stable dosage forms of levomilnacipran	02 Mar, 2031 (6 years from now)	Active
USRE43879	Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug	11 Jan, 2026 (1 year, 1 month from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fetzima's drug page

20. Gelnique

Gelnique is protected by 7 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8920392	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	26 Mar, 2031 (6 years from now)	Active
US10449173	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	06 Nov, 2029 (4 years from now)	Active
US9259388	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	06 Nov, 2029 (4 years from now)	Active
US10272061	Compositions and methods for unoccluded transdermal oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US7029694	Compositions and methods for transdermal oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US7179483	Compositions and methods for transdermal oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US8241662	Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gelnique's drug page

21. Kaletra

Kaletra is protected by 49 patents, out of which 38 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8025899 (Pediatric)	Solid pharmaceutical dosage form	14 Jun, 2028 (3 years from now)	Active
US8377952 (Pediatric)	Solid pharmaceutical dosage formulation	22 Apr, 2028 (3 years from now)	Active
US8025899	Solid pharmaceutical dosage form	14 Dec, 2027 (3 years from now)	Active
US8377952	Solid pharmaceutical dosage formulation	22 Oct, 2027 (2 years from now)	Active
US8470347 (Pediatric)	Self-emulsifying active substance formulation and use of this formulation	17 Mar, 2027 (2 years from now)	Active
US8470347	Self-emulsifying active substance formulation and use of this formulation	17 Sep, 2026 (1 year, 10 months from now)	Active
US8309613 (Pediatric)	Solid pharmaceutical dosage form	24 Jun, 2025 (7 months from now)	Active
US8268349 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8399015 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8691878 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8309613	Solid pharmaceutical dosage form	24 Dec, 2024 (a month from now)	Active
US8268349	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US8399015	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US8691878	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US6911214 (Pediatric)	Flavoring systems for pharmaceutical compositions and methods of making such compositions	28 May, 2022 (2 years ago)	Expired
US6911214	Flavoring systems for pharmaceutical compositions and methods of making such compositions	28 Nov, 2021 (2 years ago)	Expired
US8501219	Flavoring systems for pharmaceutical compositions and methods of making such compositions	28 Nov, 2021 (2 years ago)	Expired
US7364752 (Pediatric)	Solid dispersion pharamaceutical formulations	10 May, 2021 (3 years ago)	Expired
US7141593 (Pediatric)	Pharmaceutical formulations	22 Nov, 2020 (3 years ago)	Expired
US7432294 (Pediatric)	Pharmaceutical formulations	22 Nov, 2020 (3 years ago)	Expired
US7364752	Solid dispersion pharamaceutical formulations	10 Nov, 2020 (4 years ago)	Expired
US7141593	Pharmaceutical formulations	22 May, 2020 (4 years ago)	Expired
US7432294	Pharmaceutical formulations	22 May, 2020 (4 years ago)	Expired
US7148359 (Pediatric)	Polymorph of a pharmaceutical	19 Jan, 2020 (4 years ago)	Expired
US7148359	Polymorph of a pharmaceutical	19 Jul, 2019 (5 years ago)	Expired
US6232333 (Pediatric)	Pharmaceutical composition	07 May, 2018 (6 years ago)	Expired
US6458818 (Pediatric)	Pharmaceutical composition	07 May, 2018 (6 years ago)	Expired
US6521651 (Pediatric)	Pharmaceutical composition	07 May, 2018 (6 years ago)	Expired
US6232333	Pharmaceutical composition	07 Nov, 2017 (7 years ago)	Expired
US6458818	Pharmaceutical composition	07 Nov, 2017 (7 years ago)	Expired
US6521651	Pharmaceutical composition	07 Nov, 2017 (7 years ago)	Expired
US6037157 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (7 years ago)	Expired
US6703403 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (7 years ago)	Expired
US6284767 (Pediatric)	Retroviral protease inhibiting compounds	15 Aug, 2016 (8 years ago)	Expired
US6037157	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired
US6703403	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired
US5914332 (Pediatric)	Retroviral protease inhibiting compounds	13 Jun, 2016 (8 years ago)	Expired
US6284767	Retroviral protease inhibiting compounds	15 Feb, 2016 (8 years ago)	Expired
US5914332	Retroviral protease inhibiting compounds	13 Dec, 2015 (8 years ago)	Expired
US5648497 (Pediatric)	Retroviral protease inhibiting compounds	15 Jan, 2015 (9 years ago)	Expired
US5484801 (Pediatric)	Pharmaceutical composition for inhibiting HIV protease	28 Jul, 2014 (10 years ago)	Expired
US5648497	Retroviral protease inhibiting compounds	15 Jul, 2014 (10 years ago)	Expired
US5886036 (Pediatric)	Retroviral protease inhibiting compounds	19 May, 2014 (10 years ago)	Expired
US5948436 (Pediatric)	Pharmaceutical composition	13 Mar, 2014 (10 years ago)	Expired
US5541206 (Pediatric)	Retroviral protease inhibiting compounds	30 Jan, 2014 (10 years ago)	Expired
US5484801	Pharmaceutical composition for inhibiting HIV protease	28 Jan, 2014 (10 years ago)	Expired
US5886036	Retroviral protease inhibiting compounds	19 Nov, 2013 (10 years ago)	Expired
US5948436	Pharmaceutical composition	13 Sep, 2013 (11 years ago)	Expired
US5541206	Retroviral protease inhibiting compounds	30 Jul, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kaletra's drug page

22. Kybella

Kybella is protected by 15 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10500214	Formulations of deoxycholic acid and salts thereof	02 Mar, 2030 (5 years from now)	Active
US8101593	Formulations of deoxycholic acid and salts thereof	02 Mar, 2030 (5 years from now)	Active
US8367649	Formulations of deoxycholic acid and salts thereof	02 Mar, 2030 (5 years from now)	Active
US8653058	Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits	02 Mar, 2030 (5 years from now)	Active
US8242294	Synthetic bile acid compositions and methods	16 May, 2028 (3 years from now)	Active
US8461140	Synthetic bile acid compositions and methods	21 Feb, 2028 (3 years from now)	Active
US8546367	Synthetic bile acid compositions and methods	21 Feb, 2028 (3 years from now)	Active
US8883770	Synthetic bile acid compositions and methods	21 Feb, 2028 (3 years from now)	Active
US9522155	Synthetic bile acid compositions and methods	21 Feb, 2028 (3 years from now)	Active
US9636349	Synthetic bile acid compositions and methods	21 Feb, 2028 (3 years from now)	Active
US9949986	Synthetic bile acid compositions and methods	21 Feb, 2028 (3 years from now)	Active
US7622130	Methods and compositions for the non-surgical removal of fat	10 Dec, 2027 (3 years from now)	Active
US7754230	Methods and related compositions for reduction of fat	10 Dec, 2027 (3 years from now)	Active
US8298556	Methods and related compositions for the non-surgical removal of fat	03 Aug, 2025 (8 months from now)	Active
US8846066	Methods and related compositions for reduction of fat and skin tightening	08 Feb, 2025 (2 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kybella's drug page

23. Lastacaft

Lastacaft is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8664215	Ocular allergy treatments with alcaftadine	23 Dec, 2027 (3 years from now)	Active
US10617695	Ophthalmic compositions containing alcaftadine	19 Mar, 2027 (2 years from now)	Active
US5468743	Imidazo[2,1-b]benzazepine derivatives, compositions and method of use	21 Nov, 2013 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lastacaft's drug page

24. Latisse

Latisse is protected by 16 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7351404	Method of enhancing hair growth	25 May, 2024 (5 months ago)	Expired
US8101161	Method of enhancing hair growth	25 May, 2024 (5 months ago)	Expired
US8038988	Method of enhancing hair growth	25 Aug, 2023 (1 year, 2 months ago)	Expired
US8263054	Method of enhancing hair growth	25 Aug, 2023 (1 year, 2 months ago)	Expired
US8632760	Method of enhancing hair growth	15 Jan, 2023 (1 year, 10 months ago)	Expired
US8758733	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	15 Jan, 2023 (1 year, 10 months ago)	Expired
US8926953	Method of enhancing hair growth	15 Jan, 2023 (1 year, 10 months ago)	Expired
US8986715	Method of enhancing hair growth	15 Jan, 2023 (1 year, 10 months ago)	Expired
US9216183	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	15 Jan, 2023 (1 year, 10 months ago)	Expired
US9226931	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists	15 Jan, 2023 (1 year, 10 months ago)	Expired
US7388029	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	21 Jan, 2022 (2 years ago)	Expired
US8541466	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	31 Jan, 2021 (3 years ago)	Expired
US8906962	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	31 Jan, 2021 (3 years ago)	Expired
US9579270	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins	31 Jan, 2021 (3 years ago)	Expired
US8017655	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	27 Nov, 2012 (11 years ago)	Expired
US6403649	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents	21 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Latisse's drug page

25. Lexapro

Lexapro is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6916941 (Pediatric)	Crystalline composition containing escitalopram	12 Feb, 2023 (1 year, 9 months ago)	Expired
US7420069 (Pediatric)	Crystalline composition containing escitalopram	12 Feb, 2023 (1 year, 9 months ago)	Expired
US6916941	Crystalline composition containing escitalopram	12 Aug, 2022 (2 years ago)	Expired
US7420069	Crystalline composition containing escitalopram	12 Aug, 2022 (2 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexapro's drug page

26. Linzess

Linzess is protected by 12 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9708371	Treatments for gastrointestinal disorders	16 Aug, 2033 (8 years from now)	Active
US8748573	Formulations comprising linaclotide	30 Oct, 2031 (6 years from now)	Active
US8802628	Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration	30 Oct, 2031 (6 years from now)	Active
US10675325	Stable formulations of linaclotide	11 Aug, 2031 (6 years from now)	Active
US10702576	Stable formulations of linaclotide	11 Aug, 2031 (6 years from now)	Active
US8933030	Treatments for gastrointestinal disorders	17 Feb, 2031 (6 years from now)	Active
US7304036	Methods and compositions for the treatment of gastrointestinal disorders	30 Aug, 2026 (1 year, 9 months from now)	Active
US7371727	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024 (9 months ago)	Expired
US7704947	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024 (9 months ago)	Expired
US7745409	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024 (9 months ago)	Expired
US8080526	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024 (9 months ago)	Expired
US8110553	Methods and compositions for the treatment of gastrointestinal disorders	28 Jan, 2024 (9 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Linzess's drug page

27. Lumigan

Lumigan is protected by 15 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7851504	Enhanced bimatoprost ophthalmic solution	13 Jun, 2027 (2 years from now)	Active
US8278353	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8299118	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8309605	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8338479	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8524777	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8586630	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8772338	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8933120	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US8933127	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US9155716	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US9241918	Enhanced bimatoprost ophthalmic solution	16 Mar, 2025 (3 months from now)	Active
US5688819	Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	19 Aug, 2014 (10 years ago)	Expired
US8017655	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	27 Nov, 2012 (11 years ago)	Expired
US6403649	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents	21 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumigan's drug page

28. Mavik

Mavik is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5744496	Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors	28 Apr, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavik's drug page

29. Mavyret

Mavyret is protected by 20 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11246866 (Pediatric)	Solid pharmaceutical compositions for treating HCV	24 Dec, 2036 (12 years from now)	Active
US11246866	Solid pharmaceutical compositions for treating HCV	24 Jun, 2036 (11 years from now)	Active
US9321807 (Pediatric)	Crystal forms	05 Dec, 2035 (11 years from now)	Active
USRE48923 (Pediatric)	Crystal forms	08 Nov, 2035 (10 years from now)	Active
US9321807	Crystal forms	05 Jun, 2035 (10 years from now)	Active
USRE48923	Crystal forms	08 May, 2035 (10 years from now)	Active
US10286029 (Pediatric)	Method for treating HCV	14 Sep, 2034 (9 years from now)	Active
US11484534 (Pediatric)	Methods for treating HCV	14 Sep, 2034 (9 years from now)	Active
US10286029	Method for treating HCV	14 Mar, 2034 (9 years from now)	Active
US11484534	Methods for treating HCV	14 Mar, 2034 (9 years from now)	Active
US8937150 (Pediatric)	Anti-viral compounds	18 Nov, 2032 (8 years from now)	Active
US8648037 (Pediatric)	Macrocyclic proline derived HCV serine protease inhibitors	19 Jul, 2032 (7 years from now)	Active
US8937150	Anti-viral compounds	18 May, 2032 (7 years from now)	Active
US8648037	Macrocyclic proline derived HCV serine protease inhibitors	19 Jan, 2032 (7 years from now)	Active
US9586978 (Pediatric)	Anti-viral compounds	06 May, 2031 (6 years from now)	Active
US10028937 (Pediatric)	Anti-viral compounds	10 Dec, 2030 (6 years from now)	Active
US10039754 (Pediatric)	Anti-viral compounds	10 Dec, 2030 (6 years from now)	Active
US9586978	Anti-viral compounds	06 Nov, 2030 (5 years from now)	Active
US10028937	Anti-viral compounds	10 Jun, 2030 (5 years from now)	Active
US10039754	Anti-viral compounds	10 Jun, 2030 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavyret's drug page

30. Namenda

Namenda is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5061703 (Pediatric)	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Oct, 2015 (9 years ago)	Expired
US5061703	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Apr, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namenda's drug page

31. Namenda Xr

Namenda Xr is protected by 16 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8039009 (Pediatric)	Modified release formulations of memantine oral dosage forms	24 Sep, 2029 (4 years from now)	Active
US8039009	Modified release formulations of memantine oral dosage forms	24 Mar, 2029 (4 years from now)	Active
US8168209 (Pediatric)	Method and composition for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8173708 (Pediatric)	Method and composition for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8283379 (Pediatric)	Methods and compositions for the treatment of CNS-related conditions	22 May, 2026 (1 year, 6 months from now)	Active
US8329752 (Pediatric)	Composition for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8362085 (Pediatric)	Method for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8598233 (Pediatric)	Method for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8168209	Method and composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8173708	Method and composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8283379	Methods and compositions for the treatment of CNS-related conditions	22 Nov, 2025 (1 year, 6 days from now)	Active
US8329752	Composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8362085	Method for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8598233	Method for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US5061703 (Pediatric)	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Oct, 2015 (9 years ago)	Expired
US5061703	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Apr, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namenda Xr's drug page

32. Namzaric

Namzaric is protected by 21 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8058291	Methods and compositions for the treatment of CNS-related conditions	05 Dec, 2029 (5 years from now)	Active
US8039009 (Pediatric)	Modified release formulations of memantine oral dosage forms	24 Sep, 2029 (4 years from now)	Active
US8039009	Modified release formulations of memantine oral dosage forms	24 Mar, 2029 (4 years from now)	Active
US8168209 (Pediatric)	Method and composition for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8173708 (Pediatric)	Method and composition for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8283379 (Pediatric)	Methods and compositions for the treatment of CNS-related conditions	22 May, 2026 (1 year, 6 months from now)	Active
US8329752 (Pediatric)	Composition for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8362085 (Pediatric)	Method for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8598233 (Pediatric)	Method for administering an NMDA receptor antagonist to a subject	22 May, 2026 (1 year, 6 months from now)	Active
US8168209	Method and composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8173708	Method and composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8283379	Methods and compositions for the treatment of CNS-related conditions	22 Nov, 2025 (1 year, 6 days from now)	Active
US8293794	Methods and compositions for the treatment of CNS-related conditions	22 Nov, 2025 (1 year, 6 days from now)	Active
US8329752	Composition for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8338485	Compositions for the treatment of CNS-related conditions	22 Nov, 2025 (1 year, 6 days from now)	Active
US8338486	Methods for the treatment of CNS-related conditions	22 Nov, 2025 (1 year, 6 days from now)	Active
US8362085	Method for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US8580858	Compositions for the treatment of CNS-related conditions	22 Nov, 2025 (1 year, 6 days from now)	Active
US8598233	Method for administering an NMDA receptor antagonist to a subject	22 Nov, 2025 (1 year, 6 days from now)	Active
US5061703 (Pediatric)	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Oct, 2015 (9 years ago)	Expired
US5061703	Adamantane derivatives in the prevention and treatment of cerebral ischemia	11 Apr, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namzaric's drug page

33. Niaspan

Niaspan is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6469035	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid	15 Mar, 2018 (6 years ago)	Expired
US6080428	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	27 May, 2017 (7 years ago)	Expired
US6818229	Intermediate release nicotinic acid compositions for treating hyperlipidemia	15 Feb, 2014 (10 years ago)	Expired
US6129930	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night	20 Sep, 2013 (11 years ago)	Expired
US6406715	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles	20 Sep, 2013 (11 years ago)	Expired
US6676967	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia	20 Sep, 2013 (11 years ago)	Expired
US6746691	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics	20 Sep, 2013 (11 years ago)	Expired
US6818229	Intermediate release nicotinic acid compositions for treating hyperlipidemia	20 Sep, 2013 (11 years ago)	Expired
US7011848	Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013 (11 years ago)	Expired
US7998506	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Niaspan's drug page

34. Niaspan Titration Starter Pack

Niaspan Titration Starter Pack is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6080428	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	27 May, 2017 (7 years ago)	Expired
US6129930	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night	20 Sep, 2013 (11 years ago)	Expired
US6406715	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles	20 Sep, 2013 (11 years ago)	Expired
US6746691	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics	20 Sep, 2013 (11 years ago)	Expired
US7011848	Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Niaspan Titration Starter Pack's drug page

35. Nimbex

Nimbex is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5453510	Neuromuscular blocking agents	26 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nimbex's drug page

36. Nimbex Preservative Free

Nimbex Preservative Free is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5453510	Neuromuscular blocking agents	26 Sep, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nimbex Preservative Free's drug page

37. Norvir

Norvir is protected by 34 patents, out of which 29 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8470347 (Pediatric)	Self-emulsifying active substance formulation and use of this formulation	17 Mar, 2027 (2 years from now)	Active
US8470347	Self-emulsifying active substance formulation and use of this formulation	17 Sep, 2026 (1 year, 10 months from now)	Active
US8268349 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8399015 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8691878 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8268349	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US8399015	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US8691878	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US7364752 (Pediatric)	Solid dispersion pharamaceutical formulations	10 May, 2021 (3 years ago)	Expired
US7141593 (Pediatric)	Pharmaceutical formulations	22 Nov, 2020 (3 years ago)	Expired
US7432294 (Pediatric)	Pharmaceutical formulations	22 Nov, 2020 (3 years ago)	Expired
US7364752	Solid dispersion pharamaceutical formulations	10 Nov, 2020 (4 years ago)	Expired
US7141593	Pharmaceutical formulations	22 May, 2020 (4 years ago)	Expired
US7432294	Pharmaceutical formulations	22 May, 2020 (4 years ago)	Expired
US7148359 (Pediatric)	Polymorph of a pharmaceutical	19 Jan, 2020 (4 years ago)	Expired
US7148359	Polymorph of a pharmaceutical	19 Jul, 2019 (5 years ago)	Expired
US6232333 (Pediatric)	Pharmaceutical composition	07 May, 2018 (6 years ago)	Expired
US6232333	Pharmaceutical composition	07 Nov, 2017 (7 years ago)	Expired
US6037157 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (7 years ago)	Expired
US6703403 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (7 years ago)	Expired
US6037157	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired
US6703403	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired
US5648497 (Pediatric)	Retroviral protease inhibiting compounds	15 Jan, 2015 (9 years ago)	Expired
US5484801 (Pediatric)	Pharmaceutical composition for inhibiting HIV protease	28 Jul, 2014 (10 years ago)	Expired
US5648497	Retroviral protease inhibiting compounds	15 Jul, 2014 (10 years ago)	Expired
US5948436 (Pediatric)	Pharmaceutical composition	13 Mar, 2014 (10 years ago)	Expired
US5541206 (Pediatric)	Retroviral protease inhibiting compounds	30 Jan, 2014 (10 years ago)	Expired
US5635523 (Pediatric)	Retroviral protease inhibiting compounds	30 Jan, 2014 (10 years ago)	Expired
US5674882 (Pediatric)	Retroviral protease inhibiting compounds	30 Jan, 2014 (10 years ago)	Expired
US5484801	Pharmaceutical composition for inhibiting HIV protease	28 Jan, 2014 (10 years ago)	Expired
US5948436	Pharmaceutical composition	13 Sep, 2013 (11 years ago)	Expired
US5541206	Retroviral protease inhibiting compounds	30 Jul, 2013 (11 years ago)	Expired
US5635523	Retroviral protease inhibiting compounds	30 Jul, 2013 (11 years ago)	Expired
US5674882	Retroviral protease inhibiting compounds	30 Jul, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norvir's drug page

38. Oriahnn (copackaged)

Oriahnn (copackaged) is protected by 11 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11690845	Methods of administering elagolix	27 Aug, 2040 (15 years from now)	Active
US11542239	Elagolix sodium compositions and processes	23 Jul, 2039 (14 years from now)	Active
US12083227	Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis	20 Aug, 2038 (13 years from now)	Active
US10881659	Methods of treating heavy menstrual bleeding	14 Mar, 2034 (9 years from now)	Active
US11045470	Methods of treating heavy menstrual bleeding	14 Mar, 2034 (9 years from now)	Active
US7419983	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	06 Jul, 2029 (4 years from now)	Active
US11459305	Processes for the preparation of uracil derivatives	07 Nov, 2028 (3 years from now)	Active
US7056927	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	10 Sep, 2024 (2 months ago)	Expired
US7179815	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	07 Mar, 2021 (3 years ago)	Expired
US6872728	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	25 Jan, 2021 (3 years ago)	Expired
US7462625	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	25 Jan, 2021 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oriahnn (copackaged)'s drug page

39. Orilissa

Orilissa is protected by 13 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11690845	Methods of administering elagolix	27 Aug, 2040 (15 years from now)	Active
US11542239	Elagolix sodium compositions and processes	23 Jul, 2039 (14 years from now)	Active
US11690854	Methods of treating heavy menstrual bleeding	19 Apr, 2038 (13 years from now)	Active
US10537572	Methods of administering elagolix	01 Sep, 2036 (11 years from now)	Active
US10682351	Methods of administering elagolix	01 Sep, 2036 (11 years from now)	Active
US11344551	Methods of treating heavy menstrual bleeding	14 Mar, 2034 (9 years from now)	Active
US11707464	Methods of treating heavy menstrual bleeding	14 Mar, 2034 (9 years from now)	Active
US7419983	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	06 Jul, 2029 (4 years from now)	Active
US7056927	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	10 Sep, 2024 (2 months ago)	Expired
US7176211	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	06 Jul, 2024 (4 months ago)	Expired
US7179815	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	07 Mar, 2021 (3 years ago)	Expired
US6872728	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	25 Jan, 2021 (3 years ago)	Expired
US7462625	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	25 Jan, 2021 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orilissa's drug page

40. Oxytrol For Women

Oxytrol For Women is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6743441	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US7081249	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US7081250	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US7081251	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US7081252	Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US7179483	Compositions and methods for transdermal oxybutynin therapy	26 Apr, 2020 (4 years ago)	Expired
US5601839	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	26 Apr, 2015 (9 years ago)	Expired
US5834010	Triacetin as a penetration enhancer for transdermal delivery of a basic drug	26 Apr, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxytrol For Women's drug page

41. Ozurdex

Ozurdex is protected by 17 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6899717	Methods and apparatus for delivery of ocular implants	01 Nov, 2023 (1 year, 15 days ago)	Expired
US10076526	Ocular implant made by a double extrusion process	09 Jan, 2023 (1 year, 10 months ago)	Expired
US10702539	Ocular implant made by a double extrusion process	09 Jan, 2023 (1 year, 10 months ago)	Expired
US8034366	Ocular implant made by a double extrusion process	09 Jan, 2023 (1 year, 10 months ago)	Expired
US8034370	Ocular implant made by a double extrusion process	09 Jan, 2023 (1 year, 10 months ago)	Expired
US8506987	Ocular implant made by a double extrusion process	09 Jan, 2023 (1 year, 10 months ago)	Expired
US9192511	Ocular implant made by a double extrusion process	09 Jan, 2023 (1 year, 10 months ago)	Expired
US7767223	Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use	28 Nov, 2021 (2 years ago)	Expired
US6726918	Methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020 (4 years ago)	Expired
US7033605	Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor	20 Oct, 2020 (4 years ago)	Expired
US8043628	Methods for reducing edema	20 Oct, 2020 (4 years ago)	Expired
US8063031	Implants and methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020 (4 years ago)	Expired
US8088407	Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor	20 Oct, 2020 (4 years ago)	Expired
US9012437	Implants and methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020 (4 years ago)	Expired
US9283178	Methods for treating edema in the eye and intraocular implants for use therefor	20 Oct, 2020 (4 years ago)	Expired
US9592242	Methods for treating edema in the eye and intraocular implants for use therefor	20 Oct, 2020 (4 years ago)	Expired
US9775849	Implants and methods for treating inflammation-mediated conditions of the eye	20 Oct, 2020 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ozurdex's drug page

42. Qulipta

Qulipta is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10117836	Tablet formulation for CGRP active compounds	30 Jan, 2035 (10 years from now)	Active
US9850246	Process for making CGRP receptor antagonists	13 Mar, 2033 (8 years from now)	Active
US8754096	Piperidinone carboxamide azaindane CGRP receptor antagonists	19 Jul, 2032 (7 years from now)	Active
US9499545	Piperidinone carboxamide azaindane CGRP receptor antagonists	10 Nov, 2031 (6 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qulipta's drug page

43. Rectiv

Rectiv is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7189761	Nitric oxide donor composition and method for treatment of anal disorders	27 May, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rectiv's drug page

44. Restasis

Restasis is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8629111	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8633162	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8642556	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8648048	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8685930	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US9248191	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US5474979	Nonirritating emulsions for sensitive tissue	17 May, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Restasis's drug page

45. Restasis Multidose

Restasis Multidose is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9669974	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	11 May, 2034 (9 years from now)	Active
US9676525	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	07 Feb, 2034 (9 years from now)	Active
US8561859	Dispensing device	16 Apr, 2032 (7 years from now)	Active
US8292129	Dispensing device	25 Feb, 2031 (6 years from now)	Active
US8629111	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8633162	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8642556	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8648048	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US8685930	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired
US9248191	Methods of providing therapeutic effects using cyclosporin components	27 Aug, 2024 (2 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Restasis Multidose's drug page

46. Rinvoq

Rinvoq is protected by 37 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11564922	Methods of treating crohn's disease and ulcerative colitis	09 Mar, 2038 (13 years from now)	Active
US11607411	Methods of treating Crohn's disease and ulcerative colitis	09 Mar, 2038 (13 years from now)	Active
US10202393	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10344036	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10519164	Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10550126	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10597400	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10730883	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10981923	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10981924	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US10995095	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11186584	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11198697	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11365198	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11512092	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11524964	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11535624	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11535625	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11535626	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11661425	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11680069	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11718627	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11767326	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11773105	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11773106	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11780847	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11780848	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11787815	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11795175	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11976077	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof	17 Oct, 2036 (11 years from now)	Active
US11993605	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11993606	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US12077545	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US9951080	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US9963459	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
USRE47221	Tricyclic compounds	16 Aug, 2033 (8 years from now)	Active
US8962629	Tricyclic compounds	15 Jan, 2031 (6 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rinvoq's drug page

47. Rinvoq Lq

Rinvoq Lq is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10981923	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11186584	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11661425	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11680069	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11718627	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US11773105	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
US9951080	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	17 Oct, 2036 (11 years from now)	Active
USRE47221	Tricyclic compounds	16 Aug, 2033 (8 years from now)	Active
US8962629	Tricyclic compounds	15 Jan, 2031 (6 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rinvoq Lq's drug page

48. Savella

Savella is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7994220	Milnacipran for the long-term treatment of fibromyalgia syndrome	19 Sep, 2029 (4 years from now)	Active
US6602911	Methods of treating fibromyalgia	14 Jan, 2023 (1 year, 10 months ago)	Expired
US6992110	Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain	05 Nov, 2021 (3 years ago)	Expired
US7888342	Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain	05 Nov, 2021 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Savella's drug page

49. Simcor

Simcor is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6469035	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid	15 Mar, 2018 (6 years ago)	Expired
US6080428	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	27 May, 2017 (7 years ago)	Expired
US6129930	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night	20 Sep, 2013 (11 years ago)	Expired
US6406715	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles	20 Sep, 2013 (11 years ago)	Expired
US6676967	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia	20 Sep, 2013 (11 years ago)	Expired
US6746691	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics	20 Sep, 2013 (11 years ago)	Expired
US6818229	Intermediate release nicotinic acid compositions for treating hyperlipidemia	20 Sep, 2013 (11 years ago)	Expired
US7011848	Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013 (11 years ago)	Expired
US7998506	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor	20 Sep, 2013 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Simcor's drug page

50. Tarka

Tarka is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5721244	Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs	24 Feb, 2015 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tarka's drug page

51. Technivie

Technivie is protected by 19 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8691938	Anti-viral compounds	13 Apr, 2032 (7 years from now)	Active
US8420596 (Pediatric)	Macrocyclic hepatitis C serine protease inhibitors	10 Oct, 2031 (6 years from now)	Active
US8686026	Solid compositions	09 Jun, 2031 (6 years from now)	Active
US8420596	Macrocyclic hepatitis C serine protease inhibitors	10 Apr, 2031 (6 years from now)	Active
US9044480	Compositions and methods for treating HCV	10 Apr, 2031 (6 years from now)	Active
US9006387	Anti-viral compounds	10 Jun, 2030 (5 years from now)	Active
US8642538	Macrocyclic hepatitis C serine protease inhibitors	10 Sep, 2029 (4 years from now)	Active
US8268349 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8399015 (Pediatric)	Solid pharmaceutical dosage form	25 Feb, 2025 (3 months from now)	Active
US8268349	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US8399015	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US7364752 (Pediatric)	Solid dispersion pharamaceutical formulations	10 May, 2021 (3 years ago)	Expired
US7364752	Solid dispersion pharamaceutical formulations	10 Nov, 2020 (4 years ago)	Expired
US7148359 (Pediatric)	Polymorph of a pharmaceutical	19 Jan, 2020 (4 years ago)	Expired
US7148359	Polymorph of a pharmaceutical	19 Jul, 2019 (5 years ago)	Expired
US6037157 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (7 years ago)	Expired
US6703403 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (7 years ago)	Expired
US6037157	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired
US6703403	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Technivie's drug page

52. Teflaro

Teflaro is protected by 5 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8247400	Cephem compounds useful for the treatment of bacterial infections	10 Feb, 2031 (6 years from now)	Active
US9629861	Compositions and methods for treating bacterial infections using ceftaroline	21 Sep, 2030 (5 years from now)	Active
US6906055	Phosphonocephem compound	15 Dec, 2021 (2 years ago)	Expired
US7419973	Phosphonocephem compound	15 Dec, 2021 (2 years ago)	Expired
US6417175	Phosphonocephem derivatives, process for the preparation of the same, and use thereof	17 Dec, 2018 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teflaro's drug page

53. Teveten

Teveten is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5656650	Angiotensin II receptor blocking compositions	12 Aug, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teveten's drug page

54. Teveten Hct

Teveten Hct is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5656650	Angiotensin II receptor blocking compositions	12 Aug, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teveten Hct's drug page

55. Tricor

Tricor is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7276249	Nanoparticulate fibrate formulations	21 Feb, 2023 (1 year, 8 months ago)	Expired
US7320802	Methods of treatment using nanoparticulate fenofibrate compositions	21 Feb, 2023 (1 year, 8 months ago)	Expired
US6375986	Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate	21 Sep, 2020 (4 years ago)	Expired
US6074670	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018 (6 years ago)	Expired
US6277405	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018 (6 years ago)	Expired
US6589552	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018 (6 years ago)	Expired
US6652881	Fenofibrate pharmaceutical composition having high bioavailability	09 Jan, 2018 (6 years ago)	Expired
US7037529	Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it	09 Jan, 2018 (6 years ago)	Expired
US7041319	Fenofibrate pharmaceutical composition having high bioavailabilty	09 Jan, 2018 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tricor's drug page

56. Trilipix

Trilipix is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7259186	Salts of fenofibric acid and pharmaceutical formulations thereof	07 Jan, 2025 (a month from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trilipix's drug page

57. Ubrelvy

Ubrelvy is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11717515	Treatment of migraine	22 Dec, 2041 (17 years from now)	Active
US11857542	Treatment of migraine	22 Dec, 2041 (17 years from now)	Active
US12070450	Treatment of migraine	22 Dec, 2041 (17 years from now)	Active
US10117836	Tablet formulation for CGRP active compounds	30 Jan, 2035 (10 years from now)	Active
US11925709	Tablet formulation for CGRP active compounds	30 Jan, 2035 (10 years from now)	Active
US8912210	Piperidinone carboxamide azaindane CGRP receptor antagonists	23 Dec, 2033 (9 years from now)	Active
US8754096	Piperidinone carboxamide azaindane CGRP receptor antagonists	19 Jul, 2032 (7 years from now)	Active
US9499545	Piperidinone carboxamide azaindane CGRP receptor antagonists	10 Nov, 2031 (6 years from now)	Active
US9833448	Piperidinone carboxamide azaindane CGRP receptor antagonists	10 Nov, 2031 (6 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ubrelvy's drug page

58. Ultane

Ultane is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6074668 (Pediatric)	Container for an inhalation anesthetic	09 Jul, 2018 (6 years ago)	Expired
US6074668	Container for an inhalation anesthetic	09 Jan, 2018 (6 years ago)	Expired
US5990176 (Pediatric)	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jul, 2017 (7 years ago)	Expired
US6288127 (Pediatric)	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jul, 2017 (7 years ago)	Expired
US6444859 (Pediatric)	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jul, 2017 (7 years ago)	Expired
US5990176	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jan, 2017 (7 years ago)	Expired
US6288127	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jan, 2017 (7 years ago)	Expired
US6444859	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid	27 Jan, 2017 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultane's drug page

59. Venclexta

Venclexta is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10993942	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	06 Sep, 2033 (8 years from now)	Active
US11110087	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	06 Sep, 2033 (8 years from now)	Active
US11413282	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	06 Sep, 2033 (8 years from now)	Active
US11590128	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	06 Sep, 2033 (8 years from now)	Active
US9539251	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	06 Sep, 2033 (8 years from now)	Active
US11369599	Melt-extruded solid dispersions containing an apoptosis-inducing agent	23 May, 2032 (7 years from now)	Active
US8722657	Salts and crystalline forms of an apoptosis-inducing agent	29 Jan, 2032 (7 years from now)	Active
US10730873	Salts and crystalline forms of an apoptosis-inducing agent	21 Nov, 2031 (7 years from now)	Active
US8546399	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases	27 Jun, 2031 (6 years from now)	Active
US9174982	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases	26 May, 2030 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Venclexta's drug page

60. Viberzi

Viberzi is protected by 20 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10188632	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US11007179	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US11090291	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US11160792	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US11229627	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US11311516	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US11484527	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US9675587	Opioid receptor modulator dosage formulations	14 Mar, 2033 (8 years from now)	Active
US7741356	Compounds as opioid receptor modulators	27 May, 2029 (4 years from now)	Active
US8691860	Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028 (3 years from now)	Active
US9115091	Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028 (3 years from now)	Active
US9364489	Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028 (3 years from now)	Active
US9789125	Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	07 Jul, 2028 (3 years from now)	Active
US10213415	Compounds as opioid receptor modulators	14 Mar, 2025 (3 months from now)	Active
US7786158	Compounds as opioid receptor modulators	14 Mar, 2025 (3 months from now)	Active
US8344011	Compounds as opioid receptor modulators	14 Mar, 2025 (3 months from now)	Active
US8609709	Compounds as opioid receptor modulators	14 Mar, 2025 (3 months from now)	Active
US8772325	Compounds as opioid receptor modulators	14 Mar, 2025 (3 months from now)	Active
US9205076	Compounds as opioid receptor modulators	14 Mar, 2025 (3 months from now)	Active
US9700542	Compounds as opioid receptor modulators	14 Mar, 2025 (3 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viberzi's drug page

61. Vicoprofen

Vicoprofen is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6348216	Ibuprofen and narcotic analgesic compositions	10 Jun, 2017 (7 years ago)	Expired
US6599531	Method of making ibuprofen and narcotic analgesic compositions	10 Jun, 2017 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vicoprofen's drug page

62. Viekira Pak (copackaged)

Viekira Pak (copackaged) is protected by 21 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10201542	Formulations of pyrimidinedione derivative compounds	18 Oct, 2033 (8 years from now)	Active
US9629841	Formulations of pyrimidinedione derivative compounds	18 Oct, 2033 (8 years from now)	Active
US8466159	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US8492386	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US8680106	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US8685984	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US8691938	Anti-viral compounds	13 Apr, 2032 (7 years from now)	Active
US8686026	Solid compositions	09 Jun, 2031 (6 years from now)	Active
US8420596	Macrocyclic hepatitis C serine protease inhibitors	10 Apr, 2031 (6 years from now)	Active
US9044480	Compositions and methods for treating HCV	10 Apr, 2031 (6 years from now)	Active
US9006387	Anti-viral compounds	10 Jun, 2030 (5 years from now)	Active
US8642538	Macrocyclic hepatitis C serine protease inhibitors	10 Sep, 2029 (4 years from now)	Active
US8188104	Anti-infective agents and uses thereof	17 May, 2029 (4 years from now)	Active
US8501238	Anti-infective agents and uses thereof	19 Dec, 2028 (4 years from now)	Active
US9139536	Anti-infective agents and uses thereof	09 Nov, 2028 (3 years from now)	Active
US8268349	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US8399015	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US7364752	Solid dispersion pharamaceutical formulations	10 Nov, 2020 (4 years ago)	Expired
US7148359	Polymorph of a pharmaceutical	19 Jul, 2019 (5 years ago)	Expired
US6037157	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired
US6703403	Method for improving pharmacokinetics	26 Jun, 2016 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viekira Pak (copackaged)'s drug page

63. Viekira Xr

Viekira Xr is protected by 22 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10105365	Solid antiviral dosage forms	02 Jan, 2035 (10 years from now)	Active
US9333204	Solid antiviral dosage forms	02 Jan, 2035 (10 years from now)	Active
US9744170	Solid antiviral dosage forms	02 Jan, 2035 (10 years from now)	Active
US8466159	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US8492386	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US8680106	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US8685984	Methods for treating HCV	04 Sep, 2032 (7 years from now)	Active
US10201541	Compositions and methods for treating HCV	17 May, 2032 (7 years from now)	Active
US10201584	Compositions and methods for treating HCV	17 May, 2032 (7 years from now)	Active
US8691938	Anti-viral compounds	13 Apr, 2032 (7 years from now)	Active
US8686026	Solid compositions	09 Jun, 2031 (6 years from now)	Active
US8420596	Macrocyclic hepatitis C serine protease inhibitors	10 Apr, 2031 (6 years from now)	Active
US9044480	Compositions and methods for treating HCV	10 Apr, 2031 (6 years from now)	Active
US9006387	Anti-viral compounds	10 Jun, 2030 (5 years from now)	Active
US8642538	Macrocyclic hepatitis C serine protease inhibitors	10 Sep, 2029 (4 years from now)	Active
US8188104	Anti-infective agents and uses thereof	17 May, 2029 (4 years from now)	Active
US9139536	Anti-infective agents and uses thereof	09 Nov, 2028 (3 years from now)	Active
US8501238	Anti-infective agents and uses thereof	17 Sep, 2028 (3 years from now)	Active
US8268349	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US8399015	Solid pharmaceutical dosage form	25 Aug, 2024 (2 months ago)	Expired
US7364752	Solid dispersion pharamaceutical formulations	10 Nov, 2020 (4 years ago)	Expired
US7148359	Polymorph of a pharmaceutical	19 Jul, 2019 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viekira Xr's drug page

64. Viibryd

Viibryd is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7834020 (Pediatric)	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Dec, 2022 (1 year, 11 months ago)	Expired
US8193195 (Pediatric)	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Dec, 2022 (1 year, 11 months ago)	Expired
US8236804 (Pediatric)	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride	05 Dec, 2022 (1 year, 11 months ago)	Expired
US8673921 (Pediatric)	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Dec, 2022 (1 year, 11 months ago)	Expired
US7834020	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Jun, 2022 (2 years ago)	Expired
US8193195	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Jun, 2022 (2 years ago)	Expired
US8236804	Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride	05 Jun, 2022 (2 years ago)	Expired
US8673921	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride	05 Jun, 2022 (2 years ago)	Expired
US5532241	Piperidines and piperazines	29 Sep, 2014 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viibryd's drug page

65. Vraylar

Vraylar is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7737142	(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists	17 Sep, 2029 (4 years from now)	Active
USRE47350	Pharmaceutical formulations containing dopamine receptor ligands	16 Jul, 2029 (4 years from now)	Active
USRE49110	Pharmaceutical formulations containing dopamine receptor ligands	16 Jul, 2029 (4 years from now)	Active
USRE49302	Pharmaceutical formulations containing dopamine receptor ligands	16 Jul, 2029 (4 years from now)	Active
US7943621	Salts of piperazine compounds as D3/D2 antagonists	16 Dec, 2028 (4 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vraylar's drug page

66. Vuity

Vuity is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10610518	Presbyopia treatments	24 Apr, 2039 (14 years from now)	Active
US11285134	Presbyopia treatments	24 Apr, 2039 (14 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vuity's drug page

67. Zemplar

Zemplar is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6136799 (Pediatric)	Cosolvent formulations	08 Oct, 2018 (6 years ago)	Expired
US6361758 (Pediatric)	Cosolvent formulations	08 Oct, 2018 (6 years ago)	Expired
US6136799	Cosolvent formulations	08 Apr, 2018 (6 years ago)	Expired
US6361758	Cosolvent formulations	08 Apr, 2018 (6 years ago)	Expired
US5597815 (Pediatric)	Prevention of hyperphosphatemia in kidney disorder patients	13 Jan, 2016 (8 years ago)	Expired
US5597815	Prevention of hyperphosphatemia in kidney disorder patients	13 Jul, 2015 (9 years ago)	Expired
US5587497 (Pediatric)	19-nor-vitamin D compounds	24 Jun, 2014 (10 years ago)	Expired
US5587497	19-nor-vitamin D compounds	24 Dec, 2013 (10 years ago)	Expired
US5246925 (Pediatric)	19-nor-vitamin D compounds for use in treating hyperparathyroidism	17 Oct, 2012 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zemplar's drug page

68. Zymaxid

Zymaxid is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6333045 (Pediatric)	Aqueous liquid pharmaceutical composition comprised of gatifloxacin	20 Feb, 2020 (4 years ago)	Expired
US6333045	Aqueous liquid pharmaceutical composition comprised of gatifloxacin	20 Aug, 2019 (5 years ago)	Expired
US5880283 (Pediatric)	8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same	05 Jun, 2016 (8 years ago)	Expired
US5880283	8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same	05 Dec, 2015 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zymaxid's drug page

Pharsight

Pharsight

Latest Legal Activities on Abbvie's Drug Patents

Abbvie's Drug Patent Litigations

Abbvie Drug Patents' Oppositions Filed in EPO

Abbvie's Family Patents

Abbvie Drug List

Explore Our Curated Drug Screens

Abbvie News

Related content

Have Questions?